The influence of subclonal resistance mutations on targeted cancer therapy - Schmitt, Michael W.; Loeb, Lawrence A.; Salk, Jesse J. (Nature reviews. Clinical oncology, 2016)
Keywords: 692/420/2489/68; 692/699/67/1059/2326; 692/699/67/1059/602; 692/699/67/1857; 692/700/565/1436/2185; Cancer; Care and treatment; Drug resistance; Drug Resistance, Neoplasm - genetics; ErbB Receptors - antagonists & inhibitors; Fusion Proteins, bcr-abl - antagonists & inhibitors; Gene mutations; Genes, erbB-1 - genetics; Genetic aspects; Health aspects; Humans; MAP Kinase Kinase Kinases - antagonists & inhibitors; MAP Kinase Kinase Kinases - genetics; MAP Kinase Signaling System - drug effects; Medicine & Public Health; Methods; Molecular targeted therapy; Molecular Targeted Therapy - methods; Mutation - drug effects; Mutation - genetics; Neoplasms - drug therapy; Neoplasms - genetics; Oncology; Protein-Tyrosine Kinases - antagonists & inhibitors; Proto-Oncogene Proteins B-raf - antagonists & inhibitors; Proto-Oncogene Proteins B-raf - genetics; Proto-Oncogene Proteins c-kit - antagonists & inhibitors; review-article